Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

Delayed Quote. Delayed  - 07/22 10:04:06 pm
81.59 USD   +1.48%
07/21 ELI LILLY : Diversity of Lilly's Alzheimer's Disease Pipeline Showca..
07/21 ELI LILLY : Grassi Investment Management buys $8,866,972 stake in El..
07/20 ELI LILLY : U.S. FDA expands indication for type 2 diabetes treatmen..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/07/2013 | 07:59pm CEST

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

 
   By Saabira Chaudhuri 
 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND CO
07/24 ELI LILLY : The Atlantic - Convention
07/22 ELI LILLY : The Atlantic - Convention
07/22 ELI LILLY : Assigned Patent
07/21 ELI LILLY : Trademark Application for "INPOMIA" Filed
07/21 ELI LILLY : An Application for the Trademark "CORGLUTAN" Has Been Filed by Eli L..
07/21 ELI LILLY : Investigators from Eli Lilly Have Reported New Data on Non-Small-Cel..
07/21 ELI LILLY : Trademark Application for "CORGLUTAL" Filed by Eli Lilly
07/21 ELI LILLY : Findings from Eli Lilly Broaden Understanding of Fibroblasts (Circul..
07/21 ELI LILLY : Trademark Application for "ADSOLVA" Filed
07/21 ELI LILLY : Trademark Application for "COPOMAS" Filed
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/24 MY EARNINGS GAME PLAN : July 25-27
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
07/21 FDA Experts Back Brodalumab, With Warnings
07/20 BIOTECH FORUM DAILY DIGEST : Progenics Gets Critical FDA Appoval. Spotlight On A..
07/20 New Approvals Provide Reason For Optimism In 2016
Advertisement
Financials ($)
Sales 2016 20 923 M
EBIT 2016 4 726 M
Net income 2016 3 316 M
Debt 2016 2 812 M
Yield 2016 2,51%
P/E ratio 2016 28,28
P/E ratio 2017 22,77
EV / Sales 2016 4,44x
EV / Sales 2017 4,19x
Capitalization 90 116 M
More Financials
Chart ELI LILLY AND CO
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 95,9 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John C. Lechleiter Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer
Jan M. Lundberg Executive Vice President-Science & Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO-3.17%90 116
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.13%219 526
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
More Results